Preparation and evaluation of once-daily sustained-release coated tablets of tolterodine-l-tartrate

International Journal of Pharmaceutics

Volumn 460, Issue 1-2, 2014, Pages 205-211

  Pradhan, Roshan ^a   Kim, Yong Il ^a   Chang, Sun Woo ^b   Kim, Jong Oh ^a  

^a Yeungnam University   (South Korea)

^b Dong A Pharmaceutical Company   (South Korea)

Author keywords

HPMC; Matrix tablet; Pharmacokinetics; Sustained release; Tolterodine l tartrate

Indexed keywords

DETRUSITOL SR; GLYCEROL BEHENATE; POLYMER; TOLTERODINE; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; DRUG BIOAVAILABILITY; DRUG COATING; DRUG MECHANISM; DRUG SOLUBILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MATRIX TABLET; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SUSTAINED DRUG RELEASE; TABLET COMPRESSION; TABLET FORMULATION; TABLET FRIABILITY; TABLET HARDNESS; TABLET MACHINE;

HPMC; MATRIX TABLET; PHARMACOKINETICS; SUSTAINED RELEASE; TOLTERODINE L-TARTRATE;

BENZHYDRYL COMPOUNDS; CELLULOSE; CRESOLS; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; DRUG COMPOUNDING; EXCIPIENTS; FATTY ACIDS; HARDNESS; HUMANS; METHYLCELLULOSE; PHENYLPROPANOLAMINE; SOLUBILITY; TABLETS; THERAPEUTIC EQUIVALENCY; UROLOGICAL AGENTS;

EID: 84892442021     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2013.10.040     Document Type: Article

References (23)

1. P. Abrams, R. Freeman, C. Anderstrom, and A. Mattiasson Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder Br. J. Urol. 81 1998 801 810 (Pubitemid 28300606)
2. R.A. Appell Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis Urology 50 1997 90 96
3. Q.R. Cao, J.S. Choi, Y. Liu, W.J. Xu, M. Yang, B.J. Lee, and J.H. Cui A formulation approach for development of HPMC-based sustained release tablets for tolterodine tartrate with a low release variation Drug Dev. Ind. Pharm. 2012 (Epub ahead of print)
4. H. Choi, Y. Oh, and C. Kim In situ gelling and mucoadhesive liquid suppository containing acetaminophen: enhanced bioavailability Int. J. Pharm. 165 1998 23 32 (Pubitemid 28218341)
5. P. Colombo, R. Bettini, P. Santi, A. De Ascentiis, and N.A. Peppas Analysis of the swelling and release mechanisms from drug delivery systems with emphasis on drug solubility and water transport J. Control. Release 39 1996 231 237 (Pubitemid 26194222)
6. P. Costa, and J.M. Sousa Lobo Influence of dissolution medium agitation on release profiles of sustained-release tablets Drug Dev. Ind. Pharm. 27 2001 811 817 (Pubitemid 33029506)
7. R.R. Dmochowski, and R.A. Appell Advancements in pharmacologic management of the overactive bladder Urology 56 2000 41 49
8. H.P. Drutz, R.A. Appell, D. Gleason, I. Klimberg, and S. Radomski Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder Int. Urogynecol. J. Pelvic. Floor. Dysfunct. 10 1999 283 289 (Pubitemid 29465392)
9. T. Durig, and R. Fassihi Guar-based monolithic matrix systems: effect of ionizable and non-ionizable substances and excipients on gel dynamics and release kinetics J. Control. Release 80 2002 45 56 (Pubitemid 34273747)
10. S.A. Eisen, D.K. Miller, R.S. Woodward, E. Spitznagel, and T.R. Pezybeck The effect of prescribed daily dose frequency on patient medication compliance Arch. Intern. Med. 150 1990 1881 1884 (Pubitemid 20316533)
11. M. Gibaldi, and D. Perrier Pharmacokinetics 2nd ed. 1982 Marcel Dekker New York
12. Xiao Huang, and C.S. Brazel On the importance and mechanisms of burst release in matrix-controlled drug delivery systems J. Control. Release 73 2001 121 136 (Pubitemid 32539245)
13. International Conference on Harmonization (ICH Q2A, Q2B) Guidelines on Validation of Analytical Procedures 1995
14. S.N. Makhija, and P.R. Vavia Once daily sustained release tablets of venlafaxine, a novel antidepressant Eur. J. Pharm. Biopharm. 54 2002 9 15 (Pubitemid 34663851)
15. J. Malone-Lee, B. Shaffu, C. Anand, and C. Powell Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial J. Urol. 165 2001 1452 1456 (Pubitemid 32410212)
16. S.N. Meyyanathan, S. Rajan, S. Muralidaharan, M.K. Siddaiah, K. Krishnaraj, and B. Suresh Formulation and evaluation of dextromethorphan hydrobromide sustained release tablets Drug. Deliv. 15 2008 429 435
17. F.A. Mohamed, M. Roberts, L. Seton, J.L. Ford, M. Levina, and A.R. Rajabi-Siahboomi The influence of HPMC concentration on release of theophylline or hydrocortisone from extended release mini-tablets Drug Dev. Ind. Pharm. 2012 (Epub ahead of print)
18. E. Mutschler, and H. Knauf Current status of sustained release formulations in the treatment of hypertension. An overview Clin. Pharmacokinet. 37 1999 1 6 (Pubitemid 29419543)
19. L. Nilvebrant, B. Hallen, and G. Larsson Tolterodine-a new bladder selective muscarinic receptor antagonist: preclinical pharmacological and clinical data Life Sci. 60 1997 1129 1136 (Pubitemid 27165585)
20. A. Stamm, and J.C. Tritsch Some considerations on the liberation of drugs from inert matrices Drug Dev. Ind. Pharm. 12 1986 2337 2353 (Pubitemid 17178877)
21. P. Van Kerrebroeck, K. Kreder, U. Jonas, N. Zinner, and A. Wein Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder Urology 57 2001 414 421 (Pubitemid 32192963)
22. C.S. Yong, D.X. Li, D.H. Oh, J.A. Kim, B.K. Yoo, J.S. Woo, J.D. Rhee, and H.G. Choi Retarded dissolution of ibuprofen in gelatin microcapsule by cross-linking with glutaraldehyde Arch. Pharm. Res. 29 2005 431 534
23. B. Zhang, Z. Zhang, Y. Tian, and F. Xu High performance liquid chromatography-electrospray ionization mass spectrometric determination of tolterodine tartrate in human plasma J.Chromtogr. B 824 2005 92 98 (Pubitemid 41215585)